account_balance
Investment manager · 13F filer · SEC CIK 1974915
Vestal Point Capital, LP
Reported value$4.28Bas of Jun 30, 2026
Positions68 11 new, 33 sold out
Top 10 weight50%BMRN alone is 8%
FiledAug 1445 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
BMRN
BioMarin Pharmaceutical Inc
8.1%Added
NBIX
Neurocrine Biosciences Inc
7.4%Added
ABVX
Abivax SA
7.3%Added
UTHR
United Therapeutics Corp
5.5%Added
ELVN
Enliven Therapeutics Inc
4.7%Added
NRIX
Nurix Therapeutics Inc
4.6%Added
BCAX
Bicara Therapeutics Inc
3.6%Trimmed
TSHA
Taysha Gene Therapies Inc
3.1%Added
ARWR
Arrowhead Pharmaceuticals Inc
3.0%Trimmed
ABT
Abbott Laboratories
3.0%New
58 others
49.7%
Box size is the share of the fund's reported holdings. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
What changed